Inter-laboratory variation for urine albumin among laboratories in a Swedish external quality assessment scheme 2005-2023.

Autor: Lundgren M; Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sjukhusvägen 7, 753 09 Uppsala, Sweden. Electronic address: morgan.lundgren@medsci.uu.se., Ridefelt P; Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sjukhusvägen 7, 753 09 Uppsala, Sweden., Kristoffersson C; Equalis AB, Kungsgatan 113, 753 18 Uppsala, Sweden., Samuelsson I; Equalis AB, Kungsgatan 113, 753 18 Uppsala, Sweden., Larsson A; Department of Medical Sciences, Clinical Chemistry, Uppsala University, Sjukhusvägen 7, 753 09 Uppsala, Sweden.
Jazyk: angličtina
Zdroj: Clinical biochemistry [Clin Biochem] 2024 Dec; Vol. 133-134, pp. 110825. Date of Electronic Publication: 2024 Sep 18.
DOI: 10.1016/j.clinbiochem.2024.110825
Abstrakt: Introduction: Increased albuminuria is associated with elevated mortality. Urine albumin (U-ALB) above 20 mg/L or albumin-to-creatinine ratio (U-ACR) of 3 g/mol are indicative of moderately increased albuminuria. Due to limited standardization among U-ALB methods, diagnosis of increased albuminuria might prove difficult.
Materials and Methods: Data from Equalis's external quality assessment scheme for low U-ALB levels during 2005-2023 were categorized according to manufacturer and divided into central laboratory (CLAB) and point-of-care testing (POCT) methods. Manufacturer median values were compared to total group mean consensus values and manufacturer CV% was compared at different U-ALB levels.
Results: CLAB was generally closer to consensus values and had lower CV% than POCT at U-ALB levels around 20 mg/L. For CLAB, Roche methods were approximately equal to consensus U-ALB, Abbott 4 % above, and Siemens 5 % below. For POCT, HemoCue was 1 % below, Siemens 7 % above, and Abbott 8 % below. For U-Creatinine, all manufacturers generally had a good agreement differing on average by 1-4 % from consensus.
Conclusions: Although U-ALB methods generally meet The National Kidney Disease Education Program (NKDEP) recommendations of method bias less than 13 % and imprecision less than 30 %, differences among manufacturers have increased over the last years, with 2023 showing the largest differences between methods. This highlights the need for guidelines for albuminuria and ACR to take method differences into consideration, but also for implementation of suitable urine reference materials.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: